Malaria: Drug resistance and underfunding threaten progress towards eliminating killer disease

WHO's World Malaria Report 2025 flags rising risk: 282 million cases and 610,000 deaths in 2024 (94–95% concentrated in Africa; 75% of deaths in children under five), with eight countries reporting confirmed or suspected antimalarial drug resistance including to artemisinin and pfhrp2 deletions compromising rapid diagnostics. Global malaria funding was $3.9 billion in 2024 (about 42% of the $9.3 billion target) and ODA fell ~21%, raising the prospect of an uncontrolled resurgence and increasing near‑term demand for new antimalarial drugs, diagnostics, vaccines and strengthened surveillance in affected emerging markets.

Analysis

Market structure: Drug resistance and pfhrp2-driven RDT failures create a near-term winners’ list dominated by diversified diagnostics (Abbott, Roche), vaccine/platform incumbents (GSK) and specialty agro/chemical insecticide producers (Corteva, FMC). Losers are public-health budgets, local generic antimalarial makers dependent on a single regimen, and EM sovereign borrowers in the 11 high-burden countries facing higher health spending and weaker growth. Demand for alternative diagnostics and next-gen drugs could create incremental markets of tens of millions of tests and several hundred million dollars annually within 12–36 months, tightening pricing power for adaptable vendors.

Risk assessment: Tail risk includes an accelerated spread of artemisinin-resistant strains that could, in a 1–3 year severe scenario, raise malaria deaths by 50–100% in worst-affected areas and trigger EM growth shocks and donor flight, pressuring sovereign credit (CDS widening >200bps). Immediate signals (days–weeks) are WHO resistance confirmations and national RDT failure reports; medium-term (3–12 months) are donor funding flows and procurement awards; long-term (2–5 years) is new-drug approvals and scaled vaccine deployment. Hidden dependencies: rollout depends on donor ODA (currently 42% of target) and supply-chain capacity for nets/chemicals.

Trade implications: Favor 6–24 month long exposure to diagnostics and vaccine leaders able to retool assays and manufacture at scale (GSK: vaccine exposure; ABT, RHHBY for diagnostics) and select agrochemical names (CTVA, FMC) for insecticide demand. De-risk by cutting exposure to sovereigns/corporates concentrated in the top-11 malaria nations and rotate into supranational bonds (World Bank/IFC) offering yields +30–80bps vs core. Use targeted option protection on EMB (buy 3–6m puts 5–10% OTM) and call spreads on selected labs to express upside with defined risk.

Contrarian angles: The market underestimates the speed at which diagnostics can pivot—RDT failures create an acute procurement cycle that benefits agile, diversified diagnostics makers within 6–12 months, while longer-term drug R&D winners will take years and need public-private funding. The consensus may be overpaying for vaccine-only stories if ODA stays constrained; a mispriced trade is long diagnostics/chemical manufacturers and short EM sovereigns with high malaria burden. Historical parallel: chloroquine resistance caused outsized market/regional economic pain; absent funding increases, the worst public-health economic spillovers are underappreciated.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio long in Abbott Laboratories (ABT) using a 6–18 month horizon to capture RDT upgrade demand; size initial position 1.5% and add to 2.5% if WHO issues >2 national alerts in next 60 days.
• Initiate a 1.5% long in GSK (GSK) for vaccine/platform exposure (12–36 months); fund increases or WHO-backed procurement awards should be triggers to scale to 3% if announced within 3–9 months.
• Rotate out 50% of sovereign exposure to the top-11 malaria-burden countries within 90 days and redeploy into 2–5 year supranational bonds (World Bank/IFC) when spread over UST ≥30bps; target duration 2–4 years.
• Buy protection: purchase 3–6 month puts 5–10% OTM on EMB (iShares J.P. Morgan USD EM Bond ETF) sized ~1% portfolio to hedge EM sovereign tail risk; if EMB IV rises >35% consider layering additional protection.
• Take a 1% long in Corteva (CTVA) or FMC (FMC) to play elevated insecticide demand (12–24 months); enter incrementally and increase if WHO/UN procurement tenders for nets/chemicals exceed $200m in a single tranche.